TUDCA, a bile acid, attenuates amyloid precursor protein processing and amyloid-β deposition in APP/PS1 mice - PubMed (original) (raw)

TUDCA, a bile acid, attenuates amyloid precursor protein processing and amyloid-β deposition in APP/PS1 mice

Ana F Nunes et al. Mol Neurobiol. 2012 Jun.

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by accumulation of amyloid-β (Aβ) peptide in the hippocampus and frontal cortex of the brain, leading to progressive cognitive decline. The endogenous bile acid tauroursodeoxycholic acid (TUDCA) is a strong neuroprotective agent in several experimental models of disease, including neuronal exposure to Aβ. Nevertheless, the therapeutic role of TUDCA in AD pathology has not yet been ascertained. Here we report that feeding APP/PS1 double-transgenic mice with diet containing 0.4 % TUDCA for 6 months reduced accumulation of Aβ deposits in the brain, markedly ameliorating memory deficits. This was accompanied by reduced glial activation and neuronal integrity loss in TUDCA-fed APP/PS1 mice compared to untreated APP/PS1 mice. Furthermore, TUDCA regulated lipid-metabolism mediators involved in Aβ production and accumulation in the brains of transgenic mice. Overall amyloidogenic APP processing was reduced with TUDCA treatment, in association with, but not limited to, modulation of γ-secretase activity. Consequently, a significant decrease in Aβ(1-40) and Aβ(1-42) levels was observed in both hippocampus and frontal cortex of TUDCA-treated APP/PS1 mice, suggesting that chronic feeding of TUDCA interferes with Aβ production, possibly through the regulation of lipid-metabolism mediators associated with APP processing. These results highlight TUDCA as a potential therapeutic strategy for the prevention and treatment of AD.

PubMed Disclaimer

Similar articles

• Amyloid-β pathology is attenuated by tauroursodeoxycholic acid treatment in APP/PS1 mice after disease onset.
  Dionísio PA, Amaral JD, Ribeiro MF, Lo AC, D'Hooge R, Rodrigues CM. Dionísio PA, et al. Neurobiol Aging. 2015 Jan;36(1):228-40. doi: 10.1016/j.neurobiolaging.2014.08.034. Epub 2014 Sep 28. Neurobiol Aging. 2015. PMID: 25443293
• Tauroursodeoxycholic acid (TUDCA) supplementation prevents cognitive impairment and amyloid deposition in APP/PS1 mice.
  Lo AC, Callaerts-Vegh Z, Nunes AF, Rodrigues CM, D'Hooge R. Lo AC, et al. Neurobiol Dis. 2013 Feb;50:21-9. doi: 10.1016/j.nbd.2012.09.003. Epub 2012 Sep 10. Neurobiol Dis. 2013. PMID: 22974733
• Tauroursodeoxycholic acid suppresses amyloid β-induced synaptic toxicity in vitro and in APP/PS1 mice.
  Ramalho RM, Nunes AF, Dias RB, Amaral JD, Lo AC, D'Hooge R, Sebastião AM, Rodrigues CM. Ramalho RM, et al. Neurobiol Aging. 2013 Feb;34(2):551-61. doi: 10.1016/j.neurobiolaging.2012.04.018. Epub 2012 May 22. Neurobiol Aging. 2013. PMID: 22621777
• Evaluation and targeting of amyloid precursor protein (APP)/amyloid beta (Aβ) axis in amyloidogenic and non-amyloidogenic pathways: A time outside the tunnel.
  Al-Kuraishy HM, Jabir MS, Al-Gareeb AI, Albuhadily AK, Albukhaty S, Sulaiman GM, Batiha GE. Al-Kuraishy HM, et al. Ageing Res Rev. 2023 Dec;92:102119. doi: 10.1016/j.arr.2023.102119. Epub 2023 Nov 4. Ageing Res Rev. 2023. PMID: 37931848 Review.
• The amyloid hypothesis of Alzheimer's disease at 25 years.
  Selkoe DJ, Hardy J. Selkoe DJ, et al. EMBO Mol Med. 2016 Jun 1;8(6):595-608. doi: 10.15252/emmm.201606210. Print 2016 Jun. EMBO Mol Med. 2016. PMID: 27025652 Free PMC article. Review.

Cited by

• Gut microbiota metabolites: potential therapeutic targets for Alzheimer's disease?
  Zhang S, Lu J, Jin Z, Xu H, Zhang D, Chen J, Wang J. Zhang S, et al. Front Pharmacol. 2024 Sep 17;15:1459655. doi: 10.3389/fphar.2024.1459655. eCollection 2024. Front Pharmacol. 2024. PMID: 39355779 Free PMC article. Review.
• Emerging Roles of Bile Acids and TGR5 in the Central Nervous System: Molecular Functions and Therapeutic Implications.
  Romero-Ramírez L, Mey J. Romero-Ramírez L, et al. Int J Mol Sci. 2024 Aug 27;25(17):9279. doi: 10.3390/ijms25179279. Int J Mol Sci. 2024. PMID: 39273226 Free PMC article. Review.
• Biological effects of sodium phenylbutyrate and taurursodiol in Alzheimer's disease.
  Arnold SE, Hendrix S, Nicodemus-Johnson J, Knowlton N, Williams VJ, Burns JM, Crane M, McManus AJ, Vaishnavi SN, Arvanitakis Z, Neugroschl J, Bell K, Trombetta BA, Carlyle BC, Kivisäkk P, Dodge HH, Tanzi RE, Yeramian PD, Leslie K. Arnold SE, et al. Alzheimers Dement (N Y). 2024 Aug 9;10(3):e12487. doi: 10.1002/trc2.12487. eCollection 2024 Jul-Sep. Alzheimers Dement (N Y). 2024. PMID: 39131742 Free PMC article.
• The role of AMPKα subunit in Alzheimer's disease: In-depth analysis and future prospects.
  Xia L, Chen J, Huang J, Lin X, Jiang J, Liu T, Huang N, Luo Y. Xia L, et al. Heliyon. 2024 Jul 6;10(13):e34254. doi: 10.1016/j.heliyon.2024.e34254. eCollection 2024 Jul 15. Heliyon. 2024. PMID: 39071620 Free PMC article. Review.
• Gut microbiota-astrocyte axis: new insights into age-related cognitive decline.
  Zhang L, Wei J, Liu X, Li D, Pang X, Chen F, Cao H, Lei P. Zhang L, et al. Neural Regen Res. 2025 Apr 1;20(4):990-1008. doi: 10.4103/NRR.NRR-D-23-01776. Epub 2024 Apr 16. Neural Regen Res. 2025. PMID: 38989933 Free PMC article.

References

1. 1. Neurobiol Learn Mem. 2008 Jul;90(1):103-11 - PubMed
2. 1. FASEB J. 2005 Dec;19(14):2081-2 - PubMed
3. 1. Nat Rev Neurosci. 2009 May;10(5):333-44 - PubMed
4. 1. PLoS One. 2010 Apr 08;5(4):e9956 - PubMed
5. 1. Curr Alzheimer Res. 2004 Aug;1(3):175-81 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer

• Other Literature Sources

  • The Lens - Patent Citations Database